Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death

In September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetux...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes-da-Silva, Lígia C., Kepp, Oliver, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595598/
https://www.ncbi.nlm.nih.gov/pubmed/33178498
http://dx.doi.org/10.1080/2162402X.2020.1841393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595598/
https://www.ncbi.nlm.nih.gov/pubmed/33178498
http://dx.doi.org/10.1080/2162402X.2020.1841393

Ejemplares similares